Print

Purpose

The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.

Condition

Eligibility

Eligible Ages
Between 18 Years and 115 Years
Eligible Sex
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diagnosis of mCRPC between 01 January 2021 and 31 December 2025. - Male sex at index, where index is the date of initial mCRPC diagnosis. - Age 18 years at index.

Exclusion Criteria

• None

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Arm Groups

ArmDescriptionAssigned Intervention
mCRPC Cohort Adult male patients with a recent diagnosis of mCRPC in PRECISION.

Recruiting Locations

Novartis
East Hanover, New Jersey 07936

More Details

Status
Recruiting
Sponsor
Novartis Pharmaceuticals

Study Contact

Novartis Pharmaceuticals
+41613241111
novartis.email@novartis.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.